Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Hepatitis01:25

Hepatitis

99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

35
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
35

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Gut and liver·2026
Same author

Genomic Insights into <i>Candidozyma auris</i> Clade II: Comparative Phylogenomics and Structural Validation of Fluconazole Resistance Mechanisms.

Journal of fungi (Basel, Switzerland)·2026
Same author

Impact of CCD Inhibition on Semi-Quantitative Multiple Allergen Simultaneous Test.

Diagnostics (Basel, Switzerland)·2025
Same author

Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria.

Journal of liver cancer·2025
Same author

Oncologic impact of statin use on patients treated with hepatectomy for intrahepatic cholangiocarcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology·2025
Same author

Neuroinflammation in Adaptive Immunodeficient Mice with Colitis-like Symptoms.

Experimental neurobiology·2025

Video Experimental Relacionado

Updated: May 6, 2026

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.2K

Perfilado metabólico de la enfermedad hepática asociada a la hepatitis B Progreso: hepatitis B crónica, cirrosis y

Junsang Oh1, Kei-Anne Garcia Baritugo1, Jayoung Kim1,2

  • 1Biomedical Institute of Mycological Resource, International St. Mary's Hospital, College of Medicine, Catholic Kwandong University, Incheon 22711, Republic of Korea.

Metabolites
|August 27, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Seis metabolitos clave en la sangre, incluidos la isoleucina y el piruvato, muestran potencial como biomarcadores para etapas distintas de la hepatitis B crónica (CHB) y su progresión a cirrosis hepática y cáncer.

Palabras clave:
1H-NMREl virus de la hepatitis Bvías metabólicasMetabolomíaAnálisis multivariadoMetabólitos séricos

Más Videos Relacionados

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.7K

Videos de Experimentos Relacionados

Last Updated: May 6, 2026

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
07:54

Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy

Published on: December 15, 2011

13.2K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.7K

Área de la Ciencia:

  • Hepatología
  • Metabolomía
  • Descubrimiento de biomarcadores

Sus antecedentes:

  • La infección por el virus de la hepatitis B (VHB) puede conducir a la hepatitis B crónica (CHB).
  • CHB puede progresar a enfermedades hepáticas graves como la cirrosis hepática (CHB-LC) y el carcinoma hepatocelular (CHB-HCC).
  • La identificación de biomarcadores específicos de la etapa es crucial para controlar la progresión del VHB.

Objetivo del estudio:

  • Identificar los biomarcadores de metabolitos séricos específicos para las distintas etapas clínicas de la infección por HBV.
  • Utilización de la metabolomía basada en 1H-NMR para el descubrimiento de biomarcadores.
  • Comprender las vías metabólicas asociadas con la progresión del VHB.

Principales métodos:

  • Se empleó metabolomía basada en 1H-NMR para analizar muestras de suero.
  • Se han realizado análisis estadísticos univariados y multivariados (ANOVA con FDR, OPLS-DA, puntuación VIP).
  • Metabolitos discriminatorios identificados y validados en las diferentes etapas de la infección por el VHB.

Principales resultados:

  • Se han identificado 64 metabolitos séricos, con seis metabolitos discriminatorios principales.
  • La isoleucina, el triptófano y la histamina fueron significativos para la CHB.
  • El piruvato, el TMAO y el lactato fueron significativos para el CHB-HCC.
  • Estos metabolitos están relacionados con el metabolismo del propanoato, el metabolismo del piruvato y el efecto Warburg.

Conclusiones:

  • Los seis metabolitos identificados son prometedores como biomarcadores específicos de la etapa para CHB, CHB-LC y CHB-HCC.
  • Estos hallazgos apoyan el desarrollo de herramientas de diagnóstico basadas en la metabolomía.
  • Proporciona una base para futuras estrategias terapéuticas basadas en la metabolomía en la infección por HBV.